Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Internal Medicine | Surgery | Journal

Back to Journal Articles

Drug-Eluting Stents Beneficial for Off-Label Use

Last Updated: May 07, 2009.

 

Rates of vessel revascularization and death lower than bare-metal stents for off-label use

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients implanted with drug-eluting stents for off-label indications have lower rates of repeat target vessel revascularization and death without affecting the heart attack rate compared with bare-metal stents, according to a study in the May 12 issue of the Journal of the American College of Cardiology.

THURSDAY, May 7 (HealthDay News) -- Patients implanted with drug-eluting stents for off-label indications have lower rates of repeat target vessel revascularization and death without affecting the heart attack rate compared with bare-metal stents, according to a study in the May 12 issue of the Journal of the American College of Cardiology.

Dennis T. Ko, M.D., from the University of Toronto, and colleagues compared the long-term safety of drug-eluting stents and bare-metal stents among 6,944 patients with off-label indications (evenly matched between the two stent types) and 9,126 patients with on-label indications (evenly matched between the two stent types).

The researchers found that for off-label indications, significantly fewer patients receiving drug-eluting stents required repeat target vessel revascularization (11.6 versus 15.3 percent) or died (6.9 versus 10.5 percent) at three years. Rates of myocardial infarction were similar for the two stent types for off-label indications. For on-label indications, significantly fewer patients receiving drug-eluting stents required repeat target revascularization, although the composite rates of myocardial infarction or death were similar for the two stent types.

"For patients with off-label indications, drug-eluting stent implantation was associated with lower target vessel revascularization without an associated increase in longer-term risk of myocardial infarction or death compared with bare-metal stents," Ko and colleagues conclude.

One of the authors reported a relationship with Abbott Vascular, Medtronic, and Boston Scientific.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: ASH: Best Practice Evolving in Hypertension Treatment Next: ACOG: Medical Liability Climate Linked with C-Section Rates

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.